Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

Sato,S.; Yajima,A.; Sasaki,H.; Mizutani,K.; Honjo,H.; Yamamoto,K.; Ozaki,M.; Hasegawa,K.; Kudo,T.; Yakushiji,M.; Hatae,M.; Noda,K.

doi:10.3892/or.8.2.239

Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

Authors:
- S. Sato
- A. Yajima
- H. Sasaki
- K. Mizutani
- H. Honjo
- K. Yamamoto
- M. Ozaki
- K. Hasegawa
- T. Kudo
- M. Yakushiji
- M. Hatae
- K. Noda
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Faculty of Medicine, Tohoku University, Aoba-ku, Sendai 980-8574, Japan
Published online on: March 1, 2001 https://doi.org/10.3892/or.8.2.239
Pages: 239-244

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-derived endothelial cell growth factor (PD-ECGF). We conducted immunohistochemical staining of dThdPase to assess correlation between its expression in cancer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherapy and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor and stromal cells. Survival curves significantly differed between stromal dThdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining success of the combination therapy.